Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural China

International Journal of Cancer

Volumn 138, Issue 6, 2016, Pages 1453-1461

  Valdez, Melissa ^a   Jeronimo, Jose ^a   Bansil, Pooja ^a   Qiao, You Lin ^b   Zhao, Fang Hui ^b   Chen, Wen ^b   Zhang, Xun ^b   Kang, Le Ni ^b   Paul, Proma ^a   Bai, Ping ^b   Peck, Roger ^a   Li, Jing ^b   Chen, Feng ^b   Stoler, Mark H ^c   Castle, Philip E ^d,e  

^a PATH   (United States)

^b CANCER HOSPITAL   (China)

^c UNIVERSITY OF VIRGINIA   (United States)

^d Global Coalition Against Cervical Cancer   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

cervical cancer screening; cervical intraepithelial neoplasia; E6; HPV

Indexed keywords

PROTEIN E6; VIRUS DNA;

ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CHINA; COLPOSCOPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; FEMALE; FOLLOW UP; GYNECOLOGICAL EXAMINATION; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; REPEAT PROCEDURE; RURAL AREA; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SMEAR; VIRUS DETECTION; VISUAL INSPECTION WITH ACETIC ACID; CANCER STAGING; CLASSIFICATION; COMPLICATION; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; GENETICS; HEALTH SURVEY; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PROCEDURES; REPRODUCIBILITY; RURAL POPULATION; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

CHINA; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; NEOPLASM GRADING; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POPULATION SURVEILLANCE; REPRODUCIBILITY OF RESULTS; RURAL POPULATION; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84954368904     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29877     Document Type: Article

References (24)

1. International Agency for Research on Cancer (IARC). IARC Handbooks of Cancer Prevention: Cervix Cancer Screening, vol. 10. Lyon: IARCPress, 2005.
2. de Martel C, Ferlay J, Franceschi S, et al., Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13: 607-15.
3. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-917.
4. Sankaranarayanan R, Budukh AM, Rajkumar R., Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ. 2001; 79: 954-62.
5. Kitchener HC, Castle PE, Cox JT., Chapter 7: achievements and limitations of cervical cytology screening. Vaccine. 2006; 24: S3/63-70.
6. Yang BH, Bray FI, Parkin DM, et al., Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004; 109: 418-24.
7. World Health Organization (WHO). WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: WHO, 2013.
8. Ronco G, Dillner J, Elfstrom KM, et al., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383: 524-32.
9. Sankaranarayanan R, Nene BM, Shastri SS, et al., HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360: 1385-94.
10. Dillner J, Rebolj M, Birembaut P, et al., Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
11. Castle PE, Glass AG, Rush BB, et al., Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012; 30: 3044-50.
12. Kjaer SK, Frederiksen K, Munk C, et al., Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010; 102: 1478-88.
13. Qiao YL, Sellors JW, Eder PS, et al., A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008; 9: 929-36.
14. Schweizer J, Lu PS, Mahoney CW, et al., Feasibility study of a human papillomavirus e6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol. 2010; 48: 4646-48.
15. Zhao FH, Jeronimo J, Qiao YL, et al., An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila). 2013; 6: 938-48.
16. Pretorius RG, Zhang WH, Belinson JL, et al., Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004; 191: 430-4.
17. Qiao YL, Jeronimo J, Zhao FH, et al., Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer. 2014; 134: 2891-901.
18. Sherman ME, Lorincz AT, Scott DR, et al., Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95: 46-52.
19. Wentzensen N, Wacholder S., From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov. 2013; 3: 148-57.
20. McCredie MR, Sharples KJ, Paul C, et al., Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008; 9: 425-34.
21. Castle PE, Follansbee S, Borgonovo S, et al., A comparison of human papillomavirus genotype-specific DNA and E6/E7 mRNA detection to identify anal precancer among HIV-infected men who have sex with men. Cancer Epidemiol Biomarkers Prev. 2013; 22: 42-9.
22. Shastri SS, Mittra I, Mishra GA, et al., Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst. 2014; 106: dju009. doi: 10.1093/jnci/dju009
23. Gage JC, Castle PE., Preventing cervical cancer globally by acting locally: if not now, when? J Natl Cancer Inst. 2010; 102: 1524-27.
24. Schiffman M, Wentzensen N, Wacholder S, et al., Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011; 103: 368-83.